1-12 of 12
Erin G Reid
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 1a/b Trial of Luxeptinib (CG-806) in Patients with Relapsed/Refractory B-Cell Malignancies or Acute Myeloid Leukemia and Evaluation of New G3 Formulation

Aaron D. Goldberg, Felipe Samaniego, Maro Ohanian, Paul B. Koller, Namrata Sonia Chandhok, Ahad A. Sadiq, Daruka Mahadevan, Mohamad A. Cherry, Jessica K. Altman, John M. Burke, Michael Z. Koontz, J. C. C Villasboas, Ben K. Tomlinson, Laura E. Finn, Erin G Reid, Jason Melear, Victor Priego, Patrick Cobb, Elizabeth Heritage Cull, Paul Conkling, David Cosgrove, Lindsey E. Roeker, Eric Tam, Donna Nguyen Haney, Jia Hu, Ranjeet Sinha, Nawazish Khan, William G. Rice, Rafael Bejar
Journal: Blood
Blood (2023) 142 (Supplement 1): 5953.
https://doi.org/10.1182/blood-2023-181151
Published: 2023
Journal Articles

Development of Consensus Guidelines for Hematology Fellow Competency in Peripheral Blood Smear Review Utilizing Nominal Group Technique

Matthew L Chase, Reed E. Drews, Alfred I Lee, Erin G Reid, Aaron T. Gerds, Gabriela S. Hobbs, Leslie R Ellis, Marc S Zumberg, Jonathan Berry, Jason A Freed
Journal: Blood
Blood (2022) 140 (Supplement 1): 10781–10783.
https://doi.org/10.1182/blood-2022-159990
Published: 2022
Journal Articles

Evaluating the Impact of a Year-Long External Mentorship Pilot Program in Classical Hematology

Zoya Qureshy, Nathan T. Connell, Alfred I Lee, Allison A. King, Martina C Murphy, Erin G Reid, Soo Park
Journal: Blood
Blood (2022) 140 (Supplement 1): 1619–1620.
https://doi.org/10.1182/blood-2022-157669
Published: 2022
Journal Articles

A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-Cell Malignancies

Felipe Samaniego, Ahad A. Sadiq, Daruka Mahadevan, Michael Z. Koontz, Jose C. Villasboas, John M. Burke, Erin G Reid, Mohamad Cherry, Jason Melear, Victor Priego, Patrick Cobb, Elizabeth H. Cull, Paul Conkling, David Cosgrove, Lindsey E. Roeker, Donna Nguyen Haney, Jia Hu, Ranjeet Kumar Sinha, William G Rice, Rafael Bejar
Journal: Blood
Blood (2022) 140 (Supplement 1): 6498–6500.
https://doi.org/10.1182/blood-2022-163683
Published: 2022
Journal Articles

First-Line Treatment with R-CHOP Vs Dose-Adjusted R-EPOCH for Double-Expressor Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis

Tamer Othman, Juan Penaloza, Elizabeth A Brem, Lauren C. Pinter-Brown, Abinav Baweja, Matthew Hyun Joon Lee, Jane Ly, Jack Reid, Haifaa Abdulhaq, Daria Gaut, Caspian Oliai, Erin G. Reid, Joseph M Tuscano
Journal: Blood
Blood (2021) 138 (Supplement 1): 2509.
https://doi.org/10.1182/blood-2021-151374
Published: 2021
Journal Articles

Frequency, Histologic, and Prognostic Significance of CD30 Expression in AIDS-associated Diffuse Large B-Cell Lymphoma

Amina Chaudhry, Muhammad Junaid Tariq, Eshana Shah, Camille E. DeMarco, Erin G. Reid, Ethel Cesarman, Amy Chadburn, Paul Rubinstein
Journal: Blood
Blood (2021) 138 (Supplement 1): 1447.
https://doi.org/10.1182/blood-2021-154030
Published: 2021
Journal Articles

Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial)

Clinical Trials & Observations
Juan C. Ramos, Joseph A. Sparano, Amy Chadburn, Erin G. Reid, Richard F. Ambinder, Eric R. Siegel, Page C. Moore, Paul G. Rubinstein, Christine M. Durand, Ethel Cesarman, David Aboulafia, Robert Baiocchi, Lee Ratner, Lawrence Kaplan, Adam A. Capoferri, Jeannette Y. Lee, Ronald Mitsuyasu, Ariela Noy
Journal: Blood
Blood (2020) 136 (11): 1284–1297.
https://doi.org/10.1182/blood.2019003959
Published: 2020
Includes: Supplemental data
Journal Articles

Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085

Paul G. Rubinstein, MD, Page C. Moore, PhD, Milan Bimali, PhD, Amy Chadburn, MD, Ethel Cesarman, MD PhD, Michelle Rudek, PharmD, PhD, Lee Ratner, MD PhD, Richard F. Ambinder, MD, David H. Henry, MD, Stefan K. Barta, MD MRCP, MS, Herve Ghesquieres, MD PhD, Paul Coppo, MD PhD, Pierre Delobel, MD, Francois Boue, MD PhD, Lionel Galicier, MD, Juan Carlos Ramos, MD BS, Erin G. Reid, MD MS, Elad Sharon, MD MPH, Nicolas Mounier, MD, Caroline Besson, MD PhD, Ariela Noy, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 130.
https://doi.org/10.1182/blood-2019-126787
Published: 2019
Journal Articles

Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Krish Patel, MD, Jean-Marie Michot, MD, Asher A. Chanan-Khan, MD, Gilles A. Salles, MD PhD, Guillaume Cartron, MD PhD, Frederic Peyrade, MD, Reda Bouabdallah, Erin G. Reid, MD MS, Sheeba K. Thomas, MD, William G. Wierda, MD PhD, David Liebowitz, MD, John M. Pagel, MD PhD DSc, Vincent Ribrag, MD, M. Wayne Saville, MD, Chelsea M. Johnson, BSN, Thomas Ly, PhD, Tycel J. Phillips, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4079.
https://doi.org/10.1182/blood-2019-128564
Published: 2019
Journal Articles

Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for CLL and MCL

Michael Y. Choi, MD, Emanuela M. Ghia, PhD, Tanya Siddiqi, MD, William G. Wierda, MD PhD, Hun Ju Lee, Jacqueline C. Barrientos, MD MS, Nicole Lamanna, MD, Alec Goldenberg, Dimitrios Tzachanis, MD PhD, Erin G. Reid, MD MS, Elizabeth K Weihe, MD, Laura Z. Rassenti, PhD, Iris Isufi, MD, Stewart Bieler, BA, Xen Ianopulos, MD PhD, James B. Breitmeyer, MD PhD, Catriona Jamieson, MD PhD, Thomas J. Kipps, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1755.
https://doi.org/10.1182/blood-2019-131498
Published: 2019
Journal Articles

A Randomized Trial of EPOCH-Based Chemotherapy with Vorinostat for Highly Aggressive HIV-Associated Lymphomas: Updated Results Evaluating Impact of Diagnosis-to-Treatment Interval (DTI) and Pre-Protocol Systemic Therapy on Outcomes

Juan Carlos Ramos, MD BS, Joseph Sparano, MD, Page C. Moore, PhD, Eric Siegel, Jeannette Y Lee, PhD, Erin G. Reid, MD MS, Richard F. Ambinder, MD, Amy Chadburn, MD, Paul G. Rubinstein, MD, Christine Durand, Ethel Cesarman, MD PhD, Lee Ratner, MD PhD, Robert A Baiocchi, MD PhD, David M. Aboulafia, MD, Lawrence D Kaplan, MD, Adam Capoferri, Ronald T. Mitsuyasu, MD, Ariela Noy, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1588.
https://doi.org/10.1182/blood-2019-129687
Published: 2019
Journal Articles

PET Compared With CT As a Prognosticator After Rituximab Induction Therapy In Follicular Lymphoma: Report From The National Lymphocare Study

Ida Wong-Sefidan, MD, Michelle Byrtek, PhD, Xiaolei Zhou, MS, Jonathan W. Friedberg, MD, Christopher Flowers, MD, Brian K Link, MD, Andrew D. Zelenetz, MD, PhD, Keith L Dawson, DNP, RN, Erin G. Reid, MD, MS
Journal: Blood
Blood (2013) 122 (21): 4245.
https://doi.org/10.1182/blood.V122.21.4245.4245
Published: 2013